Free tool
FAERS Monitor: Livalo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022363 or its brand name (Livalo, Pitavastatin Calcium). Reports on generic versions are filed under their own applications.
Reports
8,612
Serious
6,027
70% of reports
Hospitalization
3,217
Death reported
706
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myalgia480
- diarrhoea393
- nausea374
- fatigue359
- anaemia300
- headache298
- dizziness297
- arthralgia295
- rash287
- off label use265
- dyspnoea260
- drug ineffective254
- malaise253
- pain in extremity253
- fall246
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 25 |
| 2007 | 38 |
| 2008 | 67 |
| 2009 | 78 |
| 2010 | 171 |
| 2011 | 274 |
| 2012 | 545 |
| 2013 | 375 |
| 2014 | 553 |
| 2015 | 660 |
| 2016 | 725 |
| 2017 | 707 |
| 2018 | 685 |
| 2019 | 656 |
| 2020 | 515 |
| 2021 | 417 |
| 2022 | 477 |
| 2023 | 419 |
| 2024 | 526 |
| 2025 | 383 |
| 2026 | 303 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,547 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 480 | 6.9 | 6.3 | 2,434 |
| anaemiaSignal | 300 | 3.8 | 3.4 | 634 |
| pain in extremitySignal | 253 | 2.1 | 1.9 | 146 |
| fall | 246 | 1.8 | 1.6 | 89 |
| arthralgia | 295 | 1.7 | 1.5 | 93 |
| rash | 287 | 1.6 | 1.4 | 67 |
| diarrhoea | 393 | 1.5 | 1.4 | 64 |
| dizziness | 297 | 1.5 | 1.3 | 43 |
| malaise | 253 | 1.4 | 1.2 | 30 |
| headache | 298 | 1.2 | 1.0 | 7 |
| nausea | 374 | 1.2 | 1.0 | 8 |
| fatigue | 359 | 1.1 | 1.0 | 5 |
| dyspnoea | 260 | 1.1 | 1.0 | 3 |
| off label use | 265 | 0.7 | 0.7 | 25 |
| drug ineffective | 254 | 0.5 | 0.4 | 161 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.